$KNW
KNOW LABS, INC.

2024 Q1 Form 10-Q Financial Statement

#000165495424001790 Filed on February 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2022 Q4
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.551M $2.011M $1.905M
YoY Change 13.74% 5.57% 56.55%
% of Gross Profit
Research & Development $2.175M $1.486M $1.743M
YoY Change -15.14% -14.72% 96.79%
% of Gross Profit
Depreciation & Amortization $19.65K $18.72K $103.2K
YoY Change -80.72% -81.85% 147.55%
% of Gross Profit
Operating Expenses $4.726M $3.498M $3.648M
YoY Change -1.67% -4.13% 16.99%
Operating Profit -$4.726M -$3.498M -$3.648M
YoY Change -1.67% -4.13% 319.49%
Interest Expense $716.8K $0.00 $227.2K
YoY Change 477.73% -100.0% -94.94%
% of Operating Profit
Other Income/Expense, Net -$671.6K $51.01K -$174.7K
YoY Change 441.26% -129.19% -96.11%
Pretax Income -$5.398M -$3.447M -$3.823M
YoY Change 9.48% -9.84% -28.63%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.398M -$3.447M -$3.823M
YoY Change 9.48% -9.84% -28.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.04 -$0.08
COMMON SHARES
Basic Shares Outstanding 81.35M shares 81.35M shares 48.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.710M $4.821M $9.680M
YoY Change -24.35% -50.19% -9.81%
Cash & Equivalents $4.710M $4.821M $9.680M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.710M $4.821M $9.680M
YoY Change -24.35% -50.19% -30.15%
LONG-TERM ASSETS
Property, Plant & Equipment $55.66K $75.30K $770.7K
YoY Change -92.05% -90.23% 14.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $163.6K $18.77K $15.77K
YoY Change 937.6% 19.02% 14.52%
Total Long-Term Assets $228.5K $191.6K $1.030M
YoY Change -75.0% -81.39% 0.33%
TOTAL ASSETS
Total Short-Term Assets $4.710M $4.821M $9.680M
Total Long-Term Assets $228.5K $191.6K $1.030M
Total Assets $4.938M $5.013M $10.71M
YoY Change -30.84% -53.19% -28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.032M $627.1K $404.6K
YoY Change 99.85% 54.98% -0.95%
Accrued Expenses $98.95K $95.95K $464.8K
YoY Change -77.22% -79.36% -69.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $2.762M $2.255M
YoY Change -100.0% 22.48% -83.14%
Long-Term Debt Due $3.820M
YoY Change
Total Short-Term Liabilities $5.063M $3.787M $3.658M
YoY Change 35.56% 3.53% -79.0%
LONG-TERM LIABILITIES
Long-Term Debt $1.630M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $45.99K
YoY Change -100.0% -73.2%
Total Long-Term Liabilities $1.630M $0.00 $45.99K
YoY Change 39224.08% -100.0% -92.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.063M $3.787M $3.658M
Total Long-Term Liabilities $1.630M $0.00 $45.99K
Total Liabilities $6.692M $3.787M $3.704M
YoY Change 79.0% 2.25% -79.45%
SHAREHOLDERS EQUITY
Retained Earnings -$130.8M -$125.4M -$105.2M
YoY Change 18.79% 19.13% 21.39%
Common Stock $82.51K $81.35K $48.21K
YoY Change 71.15% 68.74% 34.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.754M $1.226M $7.006M
YoY Change
Total Liabilities & Shareholders Equity $4.938M $5.013M $10.71M
YoY Change -30.84% -53.19% -28.05%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$5.398M -$3.447M -$3.823M
YoY Change 9.48% -9.84% -28.63%
Depreciation, Depletion And Amortization $19.65K $18.72K $103.2K
YoY Change -80.72% -81.85% 147.55%
Cash From Operating Activities -$3.655M -$3.393M -$2.917M
YoY Change 6.77% 16.29% 52.92%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $12.70K $10.85K
YoY Change -100.0% 17.02% -102.81%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$12.70K -$10.85K
YoY Change -100.0% 17.07% -97.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.543M $203.1K $14.84K
YoY Change 1268.36% -98.07%
NET CHANGE
Cash From Operating Activities -3.655M -$3.393M -$2.917M
Cash From Investing Activities 0.000 -$12.70K -$10.85K
Cash From Financing Activities 3.543M $203.1K $14.84K
Net Change In Cash -111.8K -$3.202M -$2.913M
YoY Change -96.76% 9.91% 91.11%
FREE CASH FLOW
Cash From Operating Activities -$3.655M -$3.393M -$2.917M
Capital Expenditures $0.00 $12.70K $10.85K
Free Cash Flow -$3.655M -$3.405M -$2.928M
YoY Change 5.81% 16.29% 92.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001074828
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81324546 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80358463 shares
CY2022Q4 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
48207937 shares
CY2022Q3 knwn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
21786313 shares
CY2023Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2023Q3 knwn Exercisable At End Of Period
ExercisableAtEndOfPeriod
20886313 shares
CY2022Q3 knwn Outstanding At Begenning Of Period
OutstandingAtBegenningOfPeriod
1.029
CY2023Q3 knwn Outstanding At End Of Period
OutstandingAtEndOfPeriod
1.103
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8280000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
000-30262
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
KNOW LABS, INC.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0273142
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Union Street
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 810
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023Q4 dei Entity Address Country
EntityAddressCountry
US
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98101
CY2023Q4 dei City Area Code
CityAreaCode
206
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
903-1351
CY2023Q4 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q4 dei Trading Symbol
TradingSymbol
KNW
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
81346524 shares
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4821477 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4821477 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75298 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
18767 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
97567 usd
CY2023Q4 us-gaap Assets
Assets
5013109 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81346524 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80358463 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
81347 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
80358 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126492778 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125501537 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125351041 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121840788 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1225889 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3743912 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5013109 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8265897 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1486388 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1743051 usd
CY2023Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2011246 usd
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1905071 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
3497634 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
3648122 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3497634 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3648122 usd
CY2023Q4 us-gaap Interest Income Other
InterestIncomeOther
51010 usd
CY2022Q4 us-gaap Interest Income Other
InterestIncomeOther
0 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
227170 usd
CY2023Q4 us-gaap Other Income
OtherIncome
0 usd
CY2022Q4 us-gaap Other Income
OtherIncome
52433 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51010 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-174737 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3446624 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3822859 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3446624 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3822859 usd
CY2023Q4 us-gaap Dividends Preferred Stock
DividendsPreferredStock
63629 usd
CY2022Q4 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3510253 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3822859 usd
CY2023Q4 knwn Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.04
CY2022Q4 knwn Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.08
CY2023Q4 knwn Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
81094007 shares
CY2022Q4 knwn Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
48187339 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
9862613 usd
CY2022Q4 knwn Stock Compensation Expense Employee Options
StockCompensationExpenseEmployeeOptions
744640 usd
CY2022Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2343 usd
CY2022Q4 knwn Issuance Of Common Stock For Exercise Of Warrants Amount
IssuanceOfCommonStockForExerciseOfWarrantsAmount
12500 usd
CY2022Q4 knwn Expenses For Extension Of Notes And Warrants
ExpensesForExtensionOfNotesAndWarrants
206994 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3822859 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3743912 usd
CY2023Q4 knwn Stock Compensation Expense Employee Options
StockCompensationExpenseEmployeeOptions
699246 usd
CY2023Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
26250 usd
CY2023Q4 knwn Dividends Common Stock Stocks
DividendsCommonStockStocks
0 usd
CY2023Q4 knwn Isssuance Of Common Stock For Common Stock Offering Amount
IsssuanceOfCommonStockForCommonStockOfferingAmount
203105 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3446624 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1225889 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3446624 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3822859 usd
CY2023Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18724 usd
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
103160 usd
CY2023Q4 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
699246 usd
CY2022Q4 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
744640 usd
CY2023Q4 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
26250 usd
CY2022Q4 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
47523 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
44404 usd
CY2023Q4 us-gaap Interest Expense Other
InterestExpenseOther
0 usd
CY2022Q4 us-gaap Interest Expense Other
InterestExpenseOther
206994 usd
CY2023Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3001 usd
CY2022Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1998 usd
CY2023Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-48759 usd
CY2022Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-45732 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-686006 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-146026 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3392647 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2917417 usd
CY2023Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12697 usd
CY2022Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10846 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12697 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10846 usd
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203105 usd
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2343 usd
CY2023Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2022Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12500 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203105 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14843 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3202239 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2913420 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8023716 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12593692 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4821477 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9680272 usd
CY2023Q4 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q4 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
63629 usd
CY2022Q4 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0 usd
CY2021Q4 knwn Authorized Common Stock Increased
AuthorizedCommonStockIncreased
200000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Revenue Recognition Leases
RevenueRecognitionLeases
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Revenue Recognition</em></strong><strong> </strong>– The Company determines revenue recognition from contracts with customers through the following steps:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">identification of the contract, or contracts, with the customer;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">identification of the performance obligations in the contract;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">determination of the transaction price;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">allocation of the transaction price to the performance obligations in the contract; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">recognition of the revenue when, or as, the Company satisfies a performance obligation.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. </p>
CY2023Q4 us-gaap Derivatives Methods Of Accounting Hedge Effectiveness
DerivativesMethodsOfAccountingHedgeEffectiveness
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Derivative Financial Instruments</em></strong><strong> – </strong>Pursuant to ASC 815 “Derivatives and Hedging”, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company determined that the conversion features for purposes of bifurcation within its currently outstanding convertible notes payable were immaterial and there was no derivative liability to be recorded as of December 31, 2023 and September 30, 2023.</p>
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48207937 shares
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Use of Estimates</em></strong> – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4 knwn Operating Leases Liability
OperatingLeasesLiability
106000 usd
CY2023Q3 knwn Operating Leases Liability
OperatingLeasesLiability
155000 usd
CY2023Q4 knwn Operating Leases Right Of Use Asset
OperatingLeasesRightOfUseAsset
98000 usd
CY2023Q3 knwn Operating Leases Right Of Use Asset
OperatingLeasesRightOfUseAsset
145000 usd
CY2023Q4 knwn Weighted Average Remaining Lease Term
WeightedAverageRemainingLeaseTerm
P6M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07 pure
CY2023Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
95952 usd
CY2023Q3 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
94062 usd
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
230005 usd
CY2023Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
2761931 usd
CY2023Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
2761931 usd
CY2023Q4 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
7684381 shares
CY2023Q4 us-gaap Share Price
SharePrice
0.25
CY2023Q3 knwn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
20866313 shares
CY2023Q3 knwn Outstanding At Begenning Of Period
OutstandingAtBegenningOfPeriod
1.063
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
123648 shares
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.250
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5000 shares
CY2023Q4 knwn Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice
-0.250
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q4 knwn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbe
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe
20984961 shares
CY2023Q4 knwn Outstanding At End Of Period
OutstandingAtEndOfPeriod
1.059
CY2023Q4 knwn Exercisable At End Of Period
ExercisableAtEndOfPeriod
20984961 shares
CY2023Q4 srt Federal Funds Sold Average Yield
FederalFundsSoldAverageYield
0 pure
CY2023Q4 knwn Expected Life Plants Useful Life
ExpectedLifePlantsUsefulLife
P3Y
CY2023Q4 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
1.08 pure
CY2023Q4 us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
0.0479 pure
CY2023Q4 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
20984961 usd
CY2023Q4 knwn Sharebased Compensation Arrangements By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
2539688 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.000 pure
CY2017Q2 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
3334 usd
CY2017Q2 knwn Lease Description
LeaseDescription
The monthly payment increases approximately 3% each year and the lease expired on May 31, 2022
CY2021Q4 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
2986 usd
CY2023Q2 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
2908 usd
CY2021Q2 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
8697 usd
CY2021Q2 knwn Lease Description
LeaseDescription
increases by 3% annually. The lease was terminated on February 5, 2024
CY2021Q4 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
5000 usd
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-12-31
CY2022Q4 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
2250 usd
CY2022Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-11-21

Files In Submission

Name View Source Status
0001654954-24-001790-index-headers.html Edgar Link pending
0001654954-24-001790-index.html Edgar Link pending
0001654954-24-001790.txt Edgar Link pending
0001654954-24-001790-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
knwn-20231231.xsd Edgar Link pending
knwn_10q.htm Edgar Link pending
knwn_10qimg1.jpg Edgar Link pending
knwn_ex311.htm Edgar Link pending
knwn_ex312.htm Edgar Link pending
knwn_ex321.htm Edgar Link pending
knwn_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
knwn-20231231_cal.xml Edgar Link unprocessable
knwn-20231231_def.xml Edgar Link unprocessable
knwn-20231231_lab.xml Edgar Link unprocessable
knwn-20231231_pre.xml Edgar Link unprocessable
knwn_10q_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable